ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0004981

atrial fibrillation

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. atrial fibrillation. Diseases, record MONDO_0004981. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004981

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
atrial fibrillation
Open Targets
Open Targets ID
MONDO_0004981
Open Targets
Other names
AF, AF - Atrial fibrillation, AFib, Atrial Fibrillations, Atrial fibrillation (disorder), Auricular Fibrillation, Auricular Fibrillations, Fibrillation, Atrial, Fibrillation, Auricular, Fibrillations, Atrial, Fibrillations, Auricular, atrial fibrillation (disease)
Open Targets
Disease Ontology
DOID:0060224
Disease Ontology
MeSH
D001281
MeSH
NCI Thesaurus
C50466
NCI Thesaurus
Highest stage of its drugs
Approval, for 22 of its 138 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs138

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
RIVAROXABANCHEMBL198362Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA565144Drugs and targets
APIXABANCHEMBL231779Small moleculeApprovalDailyMed and PMDA464336Drugs and targets
WARFARINCHEMBL1464Small moleculeApprovalTTD403939Drugs and targets
EDOXABANCHEMBL1269025Small moleculeApprovalPMDA272626Drugs and targets
DRONEDARONECHEMBL184412Small moleculeApprovalEMA Human Drugs262323Drugs and targets
DIGOXINCHEMBL1751Small moleculeApprovalDailyMed371414Drugs and targets
CLOPIDOGRELCHEMBL1771Small moleculeApprovalEMA Human Drugs131111Drugs and targets
DABIGATRAN ETEXILATECHEMBL539697Small moleculeApprovalPMDA111010Drugs and targets
VERNAKALANT HYDROCHLORIDECHEMBL2107383Small moleculeApprovalEMA Human Drugs544Drugs and targets
DOFETILIDECHEMBL473Small moleculeApprovalDailyMed533Drugs and targets

1 to 10 of 138

See all 138 drugs

Targets171

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRB1Adrenergic receptor16Adrenergic receptor agonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/153Drugs and targets
SCN5ASodium channel alpha subunit16Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6331Drugs and targets
ADRB2Adrenergic receptor11Adrenergic receptor agonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/154Drugs and targets
KCNH2Voltage-gated inwardly rectifying potassium channel KCNH210HERG blockerApprovalhttps://conductscience.org/library/genes/3757Drugs and targets
SCN4ASodium channel alpha subunit10Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6329Drugs and targets
SCN10ASodium channel alpha subunit9Sodium channel alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6336Drugs and targets
SCN11ASodium channel alpha subunit9Sodium channel alpha subunit blockerApprovalhttps://conductscience.org/library/genes/11280Drugs and targets
SCN1ASodium channel alpha subunit9Sodium channel alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6323Drugs and targets
SCN2ASodium channel alpha subunit9Sodium channel alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6326Drugs and targets
SCN3ASodium channel alpha subunit9Sodium channel alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6328Drugs and targets

1 to 10 of 171

See all 171 targets

Trials302

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03006341Validation of Predictors of OAC Initiation Using EMR Data140,1872019-03-22Atrial FibrillationDABIGATRAN ETEXILATE, WARFARINIts record names the diseaseClinicalTrials.gov
NCT05438888Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data77,8142024-05-20Non-valvular Atrial FibrillationAPIXABAN, WARFARINIts record names the diseaseClinicalTrials.gov
NCT03026556
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
42,5342019-06-03Atrial FibrillationAPIXABAN, DABIGATRAN, RIVAROXABANIts record names the diseaseClinicalTrials.gov
NCT00808067RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY TrialPhase 35,8972014-04-08Atrial FibrillationDABIGATRAN ETEXILATEIts record names the diseaseClinicalTrials.gov
NCT01774370SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea3,1822019-03-08Atrial FibrillationDABIGATRAN ETEXILATEIts record names the diseaseClinicalTrials.gov
NCT02164864Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)Phase 32,7252018-07-31Atrial Fibrillation, Percutaneous Coronary InterventionCLOPIDOGREL, DABIGATRAN ETEXILATE, TICAGRELORIts record names the diseaseClinicalTrials.gov
NCT01830543A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary InterventionPhase 32,1242017-07-31Atrial Fibrillation, Percutaneous Coronary InterventionRIVAROXABAN, VITAMIN KIts record names the diseaseClinicalTrials.gov
NCT02866175Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionPhase 31,5062020-05-06Atrial FibrillationCLOPIDOGREL, EDOXABAN, PRASUGREL, TICAGRELORIts record names the diseaseClinicalTrials.gov
NCT02100228Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)Phase 41,5002018-04-10Atrial FibrillationAPIXABANIts record names the diseaseClinicalTrials.gov
NCT02943785Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)Phase 31,4262022-03-24Atrial FibrillationEDOXABANIts record names the diseaseClinicalTrials.gov

1 to 10 of 302

See all 302 trials

Comparisons in its trials162

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Dabigatran 110 mg vs Dabigatran 150 mg: serious adverse events1,028 of 2,9141,106 of 2,9375,851NCT00808067Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Systemic Embolism Event0 of 7530 of 7471,500NCT02100228Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Acute Stroke Event0 of 7536 of 7471,500NCT02100228Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With All Cause Death2 of 7531 of 7471,500NCT02100228Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach383 of 753399 of 7471,500NCT02100228Trial comparisons
Edoxaban Regimen vs Vitamin K Antagonist Regimen: deaths from any cause46 of 74637 of 7401,486NCT02866175Trial comparisons
Edoxaban Regimen vs Vitamin K Antagonist Regimen: serious adverse events176 of 746175 of 7401,486NCT02866175Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Major Bleeding Event3 of 7356 of 7211,456NCT02100228Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): deaths from any cause1 of 7353 of 7211,456NCT02100228Trial comparisons
Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Clinically Relevant Non-Major Bleeding Events11 of 73513 of 7211,456NCT02100228Trial comparisons

1 to 10 of 162

See all 162 comparisons in its trials

Papers from its trials245

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
39842011RESULT1PubMed
38126206RESULT1PubMed
37025083RESULT1PubMed
36402632RESULT1PubMed
35623182RESULT1PubMed
34487722RESULT1PubMed
33461700RESULT1PubMed
33197159RESULT2PubMed
32745920RESULT1PubMed
31623498RESULT1PubMed

1 to 10 of 245

See all 245 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004981

GET https://conductscience.org/api/diseases/v1/MONDO_0004981/drugs?page=2

API referenceFor AI assistants